By JoelOctober 7, 20264 min read

A Trial That's Turning Heads — and Changing Lives

Imagine your child's body producing its own insulin again. No injections. No pump. No constant carb-counting math. For 12 adults with long-standing type 1 diabetes, that is now their reality — and the medical community is paying very close attention.

NBC Nightly News spotlighted the story this week, bringing national attention to a clinical trial quietly unfolding at the University of Chicago Medicine. The results? Every single one of the 12 participants achieved full insulin independence — meaning their bodies are now making insulin on their own, without any external doses.

What Actually Happened in This Trial?

The procedure at the center of this trial is called islet cell transplantation. Here's the plain-language version:

  • The pancreas contains tiny clusters of cells called islets. Inside those islets are the beta cells that make insulin.
  • In type 1 diabetes, the immune system mistakenly destroys those beta cells.
  • In this trial, doctors transplanted healthy donor islet cells into participants' livers through a minimally invasive procedure — essentially restocking the body's insulin-making supply.

This concept isn't brand-new, but there has always been a serious catch: to stop the body from rejecting the donated cells, patients had to take powerful immune-suppressing drugs called calcineurin inhibitors. The problem? These drugs can actually damage the very insulin-producing cells you just transplanted, and they carry serious side effects including kidney toxicity and high blood pressure.

The Game-Changer: A Gentler Anti-Rejection Drug

This is where the trial gets exciting. Researchers paired the islet transplant with a new drug called tegoprubart, made by Eledon Pharmaceuticals. Tegoprubart works differently — it targets a specific part of the immune system (a protein called CD40L) to prevent rejection, without the toxic side effects of older anti-rejection drugs.

The results, presented at the American Diabetes Association's annual scientific meeting earlier this year and now reaching mainstream audiences, are remarkable:

  • 100% of participants achieved insulin independence
  • All had an HbA1c (a measure of long-term blood sugar control) below 6.5% — well within the healthy range
  • The average HbA1c was an extraordinary 5.4% — similar to someone without diabetes
  • Zero episodes of severe low blood sugar after the transplant, even though all 12 participants had a history of dangerous hypoglycemic episodes before joining the trial
  • No signs of rejection in any patient

What This Means for Your Family — Right Now

We want to be honest with you: this trial involved adults with long-standing type 1 diabetes, not children. It was also a small pilot study of just 12 people. Larger trials will need to confirm these results, and the procedure requires donated pancreatic cells, which are in limited supply.

So this is not a cure available at your child's next appointment. But it is a genuinely significant proof of concept — evidence that, with the right combination of transplanted cells and a smarter anti-rejection drug, the body can be restored to making its own insulin.

Researchers are already exploring ways to scale this approach: using stem-cell-derived islets (so donor tissue isn't needed) and refining drugs like tegoprubart for broader use.

The Bottom Line

Every breakthrough in type 1 diabetes research is a step on a path — and this one is a big step. The science is moving faster than ever, and trials like this one are rewriting what we believe is possible.

If you'd like to follow this research or learn about clinical trials your family may one day qualify for, visit Breakthrough T1D's trial finder or speak with your child's endocrinologist.

There is real, hard-earned hope being made in laboratories and clinics right now. We'll keep bringing it to you every week.

Sources

  1. Could breakthrough new treatment cure Type 1 diabetes? — NBC Nightly News